Insider Transactions in Q2 2022 at Neogenomics Inc (NEO)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 22
2022
|
Cynthia J Dieter Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
57
-0.31%
|
-
|
|
Jun 10
2022
|
Lynn A. Tetrault Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+22.15%
|
-
|
|
Jun 10
2022
|
David Daly Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+47.52%
|
-
|
|
Jun 10
2022
|
Rachel A Stahler Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+42.17%
|
-
|
|
Jun 10
2022
|
Alison L. Hannah Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+12.65%
|
-
|
|
Jun 10
2022
|
Bruce K Crowther Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+19.28%
|
-
|
|
Jun 10
2022
|
Stephen M Kanovsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+38.59%
|
-
|
|
Jun 10
2022
|
Michael Aaron Kelly Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+43.24%
|
-
|
|
Jun 01
2022
|
Vishal Sikri President Advanced Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
148,455
+50.0%
|
-
|
|
May 18
2022
|
Lynn A. Tetrault Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,334
+7.85%
|
$23,338
$7.27 P/Share
|
|
Apr 28
2022
|
William Bonello Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,727
+2.9%
|
$40,089
$7.52 P/Share
|
|
Apr 01
2022
|
Douglas Matthew Brown Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,305
+34.15%
|
-
|
|
Apr 01
2022
|
David Sholehvar President, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct |
30,864
+50.0%
|
-
|
|
Apr 01
2022
|
William Bonello Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,305
+30.7%
|
-
|